ArticleBiology of sex differences2026
Sex differences in the clinical outcomes of chronic hepatitis B infection among paediatric patients.
Article in Biology of sex differences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe impacts of sex on treatment response in paediatric patients with chronic hepatitis B virus (HBV) infection remains incompletely understood. We aimed to analyse sex differences in antiviral treatment response in children with HBV infection.
methodsWe performed a retrospective cohort study on 236 treatment-naive children with chronic HBV infection at the Liver Disease Centre of Hunan Children's Hospital. The Cox proportional hazard regression was used to estimated treatment outcome differences between males and females.
resultsOf the 236 subjects, the median age at treatment initiation was 4 (2,7) years, and 155 (65.68%) were male. After the median follow-up (IQR) of 27 (18, 43) months, the crude cumulative incidence of HBsAg loss, HBeAg clearance and HBV DNA undetectability in patients were 48.73%, 61.02% and 89.36%, respectively. Kaplan-Meier curve showed that female patients were more likely to achieving HBsAg loss compared to male patients (58.02% vs. 43.87%, P
conclusionChildren with chronic HBV infection receiving antiviral treatment are frequently observed to achieve functional cure. Sex plays an important role in treatment response among paediatric patients, with female patients exhibiting a higher likelihood of achieving HBsAg loss, particularly after one- year of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.